18th Jan 2021 07:00
RNS Number : 9000L
Immupharma PLC
18 January 2021
18 January 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company's Financial Controller, was appointed as Company Secretary on 15 January 2021.
For further information please contact: ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman | + 44 (0) 207 152 4080 | Dimitri Dimitriou, Chief Executive Officer |
| Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 | SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge John Howes Bob Pountney SI Capital (Joint Broker) Nick Emerson | +44 (0) 203 368 3550 +44 (0) 203 815 8880 +44 (0) 1483 413500 | 4Reliance (Euronext Growth Listing Sponsor) Jean-Charles Snoy Degroof Petercam (Liquidity Provider) Erik De Clippel Backstage Communication Olivier Duquaine Gunther De Backer | +32 (0) 2 747 02 60 +32 (0) 2 287 95 34 +32 (0) 477 504 784 +32 (0) 475 903 909 |
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
[email protected] or visit
www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
COSBXGDBXXBDGBU
Related Shares:
Immupharma
